Company Filing History:
Years Active: 2017
Title: Patrick Grailhe: Innovator in Antibody Development
Introduction
Patrick Grailhe is a notable inventor based in Paris, France. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target Plasminogen Activator Inhibitor type-1 (PAI-1). His work has implications for various therapeutic applications, showcasing the potential of innovative solutions in medicine.
Latest Patents
Patrick Grailhe holds a patent for "Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof." This invention provides antibodies that specifically bind to PAI-1, along with pharmaceutical compositions and nucleic acids encoding these antibodies. The patent also includes recombinant expression vectors and host cells for producing such antibodies or their fragments. Furthermore, it outlines methods for using these antibodies to modulate PAI-1 activity or detect PAI-1 in both in vitro and in vivo settings. The disclosure emphasizes methods for creating antibodies that specifically bind to PAI-1 in its active conformational state.
Career Highlights
Patrick Grailhe is associated with Sanofi, a leading global healthcare company. His role at Sanofi allows him to contribute to groundbreaking research and development in the pharmaceutical industry. His expertise in antibody technology positions him as a key player in advancing therapeutic options for various diseases.
Collaborations
Patrick has collaborated with notable colleagues, including Alla Pritsker and Alexey Rak. These collaborations enhance the research environment and foster innovation in the development of new therapeutic strategies.
Conclusion
Patrick Grailhe's work in antibody development represents a significant advancement in biotechnology. His patent on PAI-1 targeting antibodies highlights the importance of innovation in addressing medical challenges. Through his contributions at Sanofi and collaborations with esteemed colleagues, he continues to impact the field positively.